Photo Bio Modulation (PBM) is a light-based therapy that has gained attention in ophthalmology, particularly for treating dry age-related macular degeneration (AMD). Here’s a detailed explanation based on the discussion in the podcast:
---
What is PBM?
- PBM is a non-invasive treatment that uses specific wavelengths of light to stimulate cellular activity and promote healing.
- It is different from traditional therapies like photodynamic therapy (PDT), which requires dye injections. PBM relies solely on light delivery without any additional substances.
---
The Valeda System by Lumethera
- Valeda is a multi-wavelength light delivery system developed by Lumethera for treating dry AMD.
- It uses three specific wavelengths: 590 nm, 660 nm, and 850 nm.
- The system was evaluated in the LIGHTSITE III clinical trial, a 24-month study involving 100 subjects (148 eyes) with dry AMD.
---
Key Findings from LIGHTSITE III
1. Visual Acuity Improvement:
- Patients treated with PBM showed a significant gain in visual acuity compared to the sham group.
- On average, patients gained 5 letters on the vision chart.
- Over 50% of patients gained at least one line of vision, 25% gained two lines, and 5% gained three lines.
2. Anatomic Improvements:
- Reduction in drusen volume (deposits in the retina) and slower progression of geographic atrophy (advanced dry AMD).
- These changes were visible on imaging techniques like fundus autofluorescence (FAF) and optical coherence tomography (OCT).
3. Safety Profile:
- The treatment was well-tolerated with a good safety profile.
- However, there was a slightly higher rate of exudative (wet) AMD development in the PBM group (5.4%) compared to the sham group (1.8%), which requires monitoring.
---
FDA Approval
- Based on the positive results from the LIGHTSITE III trial, the FDA approved Valeda in the fall of 2024 for treating intermediate dry AMD.
---
How PBM Works in Practice
- Treatment Schedule: Patients receive six series of treatments over four months, repeated over a 24-month period.
- Administration: The treatment is delivered by technicians, requiring no direct physician involvement during the procedure.
- Ease of Use: Unlike PDT, PBM is simpler to administer since it does not involve injections or dyes.
---
Potential Impact on Dry AMD Treatment
- PBM represents a paradigm shift in dry AMD therapy, offering a non-invasive option for patients with intermediate dry AMD.
- It complements existing treatments like geographic atrophy injections and provides hope for preserving vision in earlier stages of the disease.
---
Challenges and Considerations
1. Patient Selection:
- Determining which patients with intermediate dry AMD will benefit the most from PBM.
- Similar to how complement inhibitors are used for geographic atrophy, clear criteria for PBM eligibility are needed.
2. Logistical Implementation:
- The treatment requires multiple sessions and coordination, which may be challenging in busy retina practices.
- Potential for co-management with general ophthalmologists or optometrists to handle the workload.
3. Reimbursement and Costs:
- PBM has a Category III CPT code (09360), which insurers may or may not reimburse.
- Practices must purchase the Valeda machine and pay a per-session "click fee", a model unfamiliar to many retina specialists.
---
Expert Opinions
- Dr. M. Ali Khan: Highlighted the visual and anatomic benefits of PBM but noted the need for careful patient selection and logistical planning.
- Dr. AJ Korean: Emphasized the patient interest in PBM and the potential for real-world data to further validate its effectiveness.
---
Conclusion
PBM is a promising new therapy for dry AMD, offering a non-invasive option to improve vision and slow disease progression. While its adoption may face challenges related to logistics, reimbursement, and patient selection, it has the potential to become a valuable tool in the fight against AMD.